904

ADDITIONAL RISANKIZUMAB THERAPY IS EFFECTIVE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO DID NOT ACHIEVE CLINICAL RESPONSE TO INITIAL 12-WEEK INDUCTION THERAPY: AN ANALYSIS OF PHASE 3 INSPIRE AND COMMAND STUDIES

Date
May 20, 2024

Background: Risankizumab (RZB), an anti-interleukin 23p19 monoclonal antibody, demonstrated efficacy for moderately to severely active ulcerative colitis (UC) in the 12-week phase 3 INSPIRE induction study (NCT03398148). Some patients without a clinical response at week 12 may benefit from extended RZB treatment. We describe the efficacy and safety of extended RZB for an additional 12 weeks in patients without an initial clinical response.

Methods: Patients with moderately to severely active UC were randomized 2:1 to receive RZB 1200 mg or placebo intravenously (IV) at weeks 0, 4, and 8 in INSPIRE. Patients without clinical response per Adapted Mayo Score (AMS) to RZB at week 12 were randomized 1:1:1 to extended treatment with RZB (180 mg or 360 mg) subcutaneously (SC) at weeks 12 and 20 or RZB 1200 mg IV at weeks 12, 16, and 20. Patients with clinical response at week 24 on extended RZB SC treatment continued the same RZB SC dose every 8 weeks in the phase 3 COMMAND maintenance study (NCT03398135) for 52 weeks. Clinical response per AMS, clinical remission per AMS, endoscopic improvement, endoscopic remission, histologic-endoscopic mucosal improvement (HEMI), and safety were evaluated after extended induction at week 24 and at maintenance week 52.

Results: Among 650 patients receiving RZB induction for 12 weeks, 209 patients without clinical response per site endoscopy reading received an additional 12 weeks of RZB. At week 24, 56.3%, 57.1%, and 50.0% of patients achieved clinical response and 12.7%, 15.7%, and 8.8% of patients achieved clinical remission on RZB 180 mg SC, RZB 360 mg SC, and RZB 1200 mg IV, respectively (Fig 1). Rates of endoscopic improvement, endoscopic remission, and HEMI were similar across groups. Among the 56 and 44 patients treated with RZB 180 mg SC and RZB 360 mg SC who achieved clinical response at week 24 and continued RZB in COMMAND, 46.4% and 45.3% achieved clinical response, and 17.9% and 22.8% achieved clinical remission at maintenance week 52 (Fig 2). Rates of treatment-emergent adverse events were similar across groups at weeks 24 and 52. No new safety risks were identified.

Conclusion: In patients without clinical response after 12 weeks of RZB IV induction, an additional 12 weeks of RZB SC treatment at maintenance doses may induce clinical response and remission. Patients who respond to extended induction may continue to observe benefits at week 52. There was no observed benefit at week 24 of additional RZB IV treatment over initiation of RZB SC treatment, suggesting that the duration of RZB exposure rather than the dose may be an important factor for the induction of some patients with refractory UC.

Tracks

Related Products

Thumbnail for A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR MODULATOR VTX002 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL
EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR MODULATOR VTX002 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL
BACKGROUND: VTX002 is a novel oral selective sphingosine-1-phosphate-1 (S1P1) receptor modulator in development for the treatment of ulcerative colitis (UC)…
Thumbnail for LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Thumbnail for RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…